Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Caris Life Sciences, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.091 -- 00:00:05.677 Good day, everyone, and welcome to the Karis Life Sciences Q2 2026 earnings call. 00:00:05.677 -- 00:00:08.660 My name is Tanya, and I'll be your conference operator today. 00:00:08.660 -- 00:00:11.122 All participants are in a listen-only mode. 00:00:11.122 -- 00:00:14.666 After the prepared remarks, there will be a question-and-answer session. 00:00:14.666 -- 00:00:17.049 As a reminder, this call is being recorded. 00:00:17.049 -- 00:00:20.432 I would now like to hand the call over to Russel Denton at Karis. 00:00:20.432 -- 00:00:22.933 Please go ahead. 00:00:23.997 -- 00:00:28.859 Thank you. Earlier today, Karis Life Sciences released financial results for the quarter 00:00:28.859 -- 00:00:34.041 ended June 30th, 2026. Joining from Karis today are David Dean Halbert, 00:00:34.041 -- 00:00:39.183 our founder, chairman, and CEO, David Spetzler, our president, Brian Brille, 00:00:39.183 -- 00:00:43.985 our vice chairman and EVP, and Luke Power, our CFO. 00:00:43.985 -- 00:00:47.807 Before you begin, I'd like to remind you that during this call, management will make 00:00:47.807 -- 00:00:51.283 forward-looking statements within the meeting of federal securities laws. 00:00:51.283 -- 00:00:54.804 These statements are based on management's current expectations and involve risks and 00:00:54.804 -- 00:01:00.266 uncertainties that could cause actual results to materially differ from those anticipated. 00:01:00.266 -- 00:01:03.887 For a discussion of the factors that could affect our future results, please refer to 00:01:03.887 -- 00:01:08.809 our SEC filings, including our annual report on Form 10-K and our quarterly reports on 00:01:08.809 -- 00:01:13.530 Form 10-Q. We undertake no obligation to update these statements except as requir...